Friday, January 20, 2023

Alnylam Pharmaceuticals Starts 2023 With In-Line Revenue And A Full Slate Of Clinical Read-Outs

This will be another busy year for Alnylam Pharmaceuticals (NASDAQ:ALNY), as this leading RNAi biotech expects to release clinical updates on five different clinical programs, in addition to anticipated updates from partnered programs and multiple potential IND filings. Though the

Follow this link to the full article: 

 Alnylam Pharmaceuticals Starts 2023 With In-Line Revenue And A Full Slate Of Clinical Read-Outs

No comments: